Edgewise (EWTX) Climbs 7.96% for June 23

Equities Staff  |

Edgewise Therapeutics Inc (NASDAQ:EWTX) shares gained 7.96% today on 169,369 shares - in comparison to their 30 day average of 213,471 shares traded.

After today’s close at $8.27 the company has a 50 day moving average of $6.73.

The company is set to release earnings on 2022-08-09.

Edgewise is down 49.87% so far this year.

For technical charts, analysis, and more on Edgewise visit the company profile.

About Edgewise Therapeutics Inc

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Guided by its holistic drug discovery approach to targeting the muscle as an organ, Edgewise has combined its foundational expertise in muscle biology and small molecule engineering to build its proprietary, muscle focused drug discovery platform. Edgewise’s platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases.

To get more information on Edgewise Therapeutics Inc and to follow the company's latest updates, you can visit the company's profile page here: Edgewise Therapeutics Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Trending Articles

Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade
What You Need To Know About Bear Markets

Market Movers

Sponsored Financial Content